Atopic Dermatitis

23 competing products in clinical development for Atopic Dermatitis.

Pipeline by Phase

Phase 16

Phase 1/21

Phase 29

Phase 35

Approved2

All Products (23)

Product	Company	Stage	Status	Hype
Lebrikizumab	Eli Lilly	Approved	Recruiting	50
Alefacept	Astellas Pharma	Approved	Completed	43
Lebrikizumab	Eli Lilly	Phase 3	Completed	40
Baricitinib + Placebo + Topical corticosteroid	Eli Lilly	Phase 3	Completed	40
Lebrikizumab	Eli Lilly	Phase 3	Completed	40
Lebrikizumab	Eli Lilly	Phase 3	Completed	40
DSXS + Placebo	Sun Pharmaceutical	Phase 3	Completed	40
nemolizumab (CIM331)	Chugai Pharmaceutical	Phase 2	Completed	35
SUN13834 + Placebo	Daiichi Sankyo	Phase 2	Completed	35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061	Daiichi Sankyo	Phase 2	Completed	35
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAX	Astellas Pharma	Phase 2	Completed	35
DSXS topical	Sun Pharmaceutical	Phase 2	Completed	35
S-777469 400 mg + S-777469 800 mg + Placebo	Shionogi	Phase 2	Completed	35
KHK4083 + Placebo	Kyowa Kirin	Phase 2	Completed	35
KHK4577 + Placebo	Kyowa Kirin	Phase 2	Completed	35
50 mg S-777469 + 200 mg S-777469 + 800 mg S-777469 + Placebo	Shionogi	Phase 1/2	Completed	32
Ruxolitinib Topical Cream 1.5% + OPZELURA (Ruxolitinib) Cream + Placebo	Sun Pharmaceutical	Phase 1	Completed	29
Tacrolimus 0.1% manufactured by Taro + Protopic - Tacrolimus 0.1% + Tacrolimus Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	Completed	29
Treatment with Halobetasol propionate 0.05% topical spray	Sun Pharmaceutical	Phase 2	Terminated	27
DS-2741a + Placebo	Daiichi Sankyo	Phase 1	Terminated	21
KHK4323 IV/S + KHK4323 SC/S + KHK4323 IV/M + Placebo IV/S + Placebo IV/M + Placebo SC/S	Kyowa Kirin	Phase 1	Terminated	21
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin	Hoth Therapeutics	Phase 1	Completed	19
ENS-002	Concerto Biosciences	Phase 1	Terminated	11